Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905405 | 0.84 | PDGFRB (0.60) | PDGFRBPDGFRAEGFRFGFR1FGFR2 | |
| SCHEMBL7264558 | 0.81 | CYP11B2 (0.64) | PDGFRBPDGFRACYP2A6FGFR1KDR | |
| SCHEMBL1422588 | 0.78 | CYP19A1 (0.65) | PDGFRBPDGFRACYP2A6CYP19A1CYP11B2 | |
| SCHEMBL14905376 | 0.78 | CYP2A6 (0.60) | PDGFRBPDGFRACYP2A6EGFRFGFR1 | |
| SCHEMBL14905530 | 0.78 | PDGFRB (0.61) | PDGFRBPDGFRACYP2A6EGFRFGFR1 | |
| SCHEMBL14905514 | 0.76 | FGFR3 (0.52) | PDGFRBPDGFRACYP2A6FGFR1FGFR2 | |
| SCHEMBL8170900 | 0.75 | PDGFRB (1.00) | PDGFRBPDGFRACYP2A6EGFR | |
| SCHEMBL28138821 | 0.75 | CYP2A6 (0.67) | PDGFRBPDGFRACYP2A6EGFRCYP19A1 | |
| SCHEMBL14905216 | 0.73 | FGFR3 (0.60) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14905511 | 0.73 | PDE10A (0.48) | PDGFRBPDGFRAPDE2APDE10ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | PDGFRB 3569/4885PDGFRA 3281/4885CYP2A6 424/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | PDGFRB 3569/4885PDGFRA 3281/4885CYP2A6 424/4885 |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | NQO1, NDC1, NTPCR | PDGFRB 3222/4885PDGFRA 2879/4885CYP2A6 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.